QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon, France’s second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL. HCL researchers said the Nu.Q® Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of the reimbursement and certification processes. Data generated through collaboration with Volition indicate that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis…